Financial instruments (Tables)

6 Months Ended

Jun. 30, 2020

Financial Instruments - additional disclosure [abstract]

Fair value by hierarchy

	Level 1		Level 2		Level 3		Total
(USD millions)	Jun 30, 2020	Dec 31, 2019	Jun 30, 2020	Dec 31, 2019	Jun 30, 2020	Dec 31, 2019	Jun 30, 2020	Dec 31, 2019
Marketable securities
Debt securities			24	24			24	24
Fund investments	33	37					33	37
Total marketable securities	33	37	24	24			57	61
Derivative financial instruments			136	102			136	102
Total marketable securities and derivative financial instruments	33	37	160	126			193	163
Long-term financial investments
Debt and equity securities	904	976			539	581	1 443	1 557
Fund investments					235	233	235	233
Contingent consideration receivables					444	399	444	399
Total long-term financial investments	904	976			1 218	1 213	2 122	2 189
Associated companies at fair value through profit or loss					175	186	175	186
Contingent consideration payables					– 1 039	– 1 036	– 1 039	– 1 036
Other financial liabilities					– 20	– 29	– 20	– 29
Derivative financial instruments			– 126	– 185			– 126	– 185
Total financial liabilities at fair value			– 126	– 185	– 1 059	– 1 065	– 1 185	– 1 250

Disclosure of detailed information about borrowings

Coupon	Currency	Nominal amount (USD millions)	Maturity year	Issuer	Issue price	Carrying value Jun 30, 2020 (USD millions)
1.75%	USD	1 000	2025	Novartis Capital Corporation, New York, United States	99.852%	996
2.00%	USD	1 250	2027	Novartis Capital Corporation, New York, United States	99.909%	1 245
2.20%	USD	1 500	2030	Novartis Capital Corporation, New York, United States	99.869%	1 492
2.75%	USD	1 250	2050	Novartis Capital Corporation, New York, United States	97.712%	1 213